SpiderRock Advisors’s Moderna MRNA Stock Holding History

SpiderRock Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Hold	0	–	-$88K	–	189
2020 Q4	–	Hold	0	–	–	–	143

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SpiderRock Advisors's MRNA Position: Q3 2024 in Review

SpiderRock Advisors increased its Moderna (MRNA) stake by 1,443% in Q3 2024, buying an estimated $2.31M and bringing the position to 26,917 shares worth $1.8M. The position accounts for 0.03% of the portfolio, ranked #345.

SpiderRock Advisors first reported a position in MRNA in Q1 2024 and has held it in 3 quarters since. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

SpiderRock Advisors held 26,917 shares of Moderna worth $1.8M as of Q3 2024.
SpiderRock Advisors bought 25,172 Moderna shares in Q3 2024, an estimated $2.31M.
Moderna made up 0.03% of SpiderRock Advisors's portfolio in Q3 2024, its #345 holding.
SpiderRock Advisors first reported a position in Moderna in Q1 2024 and has held it in 3 quarters since.
788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on SpiderRock Advisors's 13F filing for Q3 2024, filed 1 Nov 2024.